Nephrology Times
Advertisement
Researchers estimated hyperkalemia incidence in patients with chronic kidney disease from routine clinical care.
Surveyed physicians indicated that IgAN patients were referred to them late and not all potential cases had a timely biopsy.
C3 plays a key role in the formation of Gd-IgA1-containing IC with a nephritogenic capacity for IgAN.
Clinical improvement does not always reflect pathology, so renal biopsy may be needed to determine IgAN treatment efficacy.
Even when levels are below the current KDIGO threshold, proteinuria in IgAN indicates a risk of kidney failure.
Researchers found evidence that anti-mesangium IgA is involved in the pathogenesis of human IgAN.
Data from patient charts and surveys of nephrologists shed light on the future of individualizing treatment for IgAN.
Recent research reveals tolvaptan’s role in reducing hemodialysis initiation risk in ADPKD,
Contrary to recommendations, low-dose tolvaptan may be an option for refractory hyponatremia in cirrhosis.
A study examined physician confidence and barriers to prescription of tolvaptan for the management of ADPKD.
A study investigated whether treatment with difelikefalin and tolvaptan can protect against worsening of late-stage PKD.
ESSENTIAL assessed the safety and effectiveness of tolvaptan among patients in Korea with ADPKD and CKD stages 1 to 3.
Tolvaptan increased serum sodium without causing sodium overcorrection in syndrome of inappropriate antidiuresis.
A biopsy registry linked with administrative databases proved to be a practical way of studying IgAN at the population level.
Researchers identified six candidate loci that were significantly associated with IgA nephropathy prognosis.
The largest SnRNA-Seq profiling of IgAN kidney cells to date identified noteworthy cell-specific pathways in IgA nephropathy.
A study examined the impact loin pain has on IgAN patients' quality of life and strategies to manage the pain.
Analysis of single-nucleus data described heterogeneity in IgAN and found pathogenic alterations in the IgAN transcriptome.
A study assessed the efficacy and safety of hyperkalemia treatment and identified risk factors associated with hypoglycemia.
Dr. Benjamin Dekel shared insights on kidney regenerative medicine with Nephrology Times.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.